title: Management of relapsed multiple myeloma after autologous stem cell transplant.
abstract: Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
authors: Sarah A
authors: SA
authors: Holstein
authors: Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors: Paul G
authors: PG
authors: Richardson
authors: Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
authors: Jacob P
authors: JP
authors: Laubach
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York. Electronic address: plmcc54@gmail.com.
authors: Philip L
authors: PL
authors: McCarthy
mesh_terms: D064592:Autografts; D003907:Dexamethasone / Q000008:administration & dosage*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D061988:Proteasome Inhibitors / Q000008:administration & dosage*; D012008:Recurrence; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D007155:Immunologic Factors; D061988:Proteasome Inhibitors; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: Monoclonal antibody; Multiple myeloma salvage autologous stem cell transplant; Relapsed/refractory; Salvage allogenic stem cell transplant